{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T17:01:29Z","timestamp":1756573289559,"version":"3.40.5"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,25]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>5-aminolevulinic acid (5-ALA), a natural amino acid that is marketed alongside sodium ferrous citrate (SFC) as a functional food, blocks severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proliferation in vitro and exerts anti-inflammatory effects. In this phase II open-label, prospective, parallel-group, randomized trial, we aimed to evaluate the safety and efficacy of 5-ALA in patients with mild-to-moderate coronavirus disease 2019.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This trial was conducted in patients receiving 5-ALA\/SFC (250\/145\u2009mg) orally thrice daily for 7 days, followed by 5-ALA\/SFC (150\/87\u2009mg) orally thrice daily for 7 days. The primary endpoints were changes in SARS-CoV-2 viral load, clinical symptom scores, and 5-ALA\/SFC safety (adverse events [AE] and changes in laboratory values and vital signs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 50 patients were enrolled from 8 institutions in Japan. The change in SARS-CoV-2 viral load from baseline was not significantly different between the 5-ALA\/SFC (n = 24) and control (n = 26) groups. The duration to improvement was shorter in the 5-ALA\/SFC group than in the control group, although the difference was not significant. The 5-ALA\/SFC group exhibited faster improvement rates in \u201ctaste abnormality,\u201d \u201ccough,\u201d \u201clethargy,\u201d and \u201cno appetite\u201d than the control group. Eight AEs were observed in the 5-ALA\/SFC group, with 22.7% of patients experiencing gastrointestinal symptoms (decreased appetite, constipation, and vomiting). AEs occurred with 750\/435\u2009mg\/day in 25.0% of patients in the first phase and with 450\/261\u2009mg\/day of 5-ALA\/SFC in 6.3% of patients in the second phase.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>5-ALA\/SFC improved some symptoms but did not influence the SARS-CoV-2 viral load or clinical symptom scores over 14 days. The safety of 5-ALA\/SFC in this study was acceptable. Further evaluation using a larger sample size or modified method is warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000034858","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T22:02:17Z","timestamp":1693432937000},"page":"e34858","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Safety and efficacy of 5-aminolevulinic acid phosphate\/iron in mild-to-moderate coronavirus disease 2019: A randomized exploratory phase II trial"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0768-9528","authenticated-orcid":false,"given":"Takeshi","family":"Tanaka","sequence":"first","affiliation":[{"name":"Infection Control and Education Center, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Infection Control and Education Center, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"},{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Infection Control and Education Center, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyomitsu","family":"Sawai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki Harbor Medical Center, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kadota","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki Harbor Medical Center, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Sasebo City General Hospital, Sasebo-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sumiyoshi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Isahaya General Hospital, Japan Community Health Care Organization, Isahaya-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Ide","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Isahaya General Hospital, Japan Community Health Care Organization, Isahaya-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuo","family":"Tachikawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Yokohama Municipal Citizen\u2019s Hospital, Yokohama-shi, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kobe City Medical Center West Hospital, Kobe-shi, Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hibino","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Fujisawa-shi, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanori","family":"Shiomi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Nagahama Red Cross Hospital, Nagahama-shi, Shiga, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Izumida","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohsuke","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momoko","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotomo","family":"Yamanashi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"},{"name":"Department of General Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Akabame","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Umeda","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masumi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Kosai","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Iwanaga","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Ashizawa","sequence":"additional","affiliation":[{"name":"Infection Control and Education Center, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"},{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki-shi, Nagasaki, Japan"},{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiga","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Clinical Development Department, Neopharma Japan Co. Ltd., Chiyoda-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koya","family":"Ariyoshi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"},{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Kita","sequence":"additional","affiliation":[{"name":"School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki-shi, Nagasaki, Japan"},{"name":"Department of Host-Defense Biochemistry, Institute of Tropical Medicine Nagasaki University, Nagasaki-shi, Nagasaki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[{"name":"Infection Control and Education Center, Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan"},{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki-shi, Nagasaki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine.","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients.","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19.","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody Sotrovimab.","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19.","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in outpatients.","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use.","volume":"386","author":"Rockett","year":"2022","journal-title":"N Engl J Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 omicron sublineages.","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.intimp.2015.11.034","article-title":"5-aminolevulinic acid regulates the inflammatory response and alloimmune reaction.","volume":"37","author":"Fujino","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.intimp.2010.11.029","article-title":"Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy.","volume":"11","author":"Ishizuka","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"4267357","DOI":"10.1155\/2019\/4267357","article-title":"Safety and mode of action of diabetes medications in comparison with 5-aminolevulinic acid (5-ALA).","volume":"2019","author":"Rehani","year":"2019","journal-title":"J Diabetes Res"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2018.05.009","article-title":"Oral administration of 5-aminolevulinic acid induces heme oxygenase-1 expression in peripheral blood mononuclear cells of healthy human subjects in combination with ferrous iron.","volume":"833","author":"Ito","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-018-0018-6","article-title":"Targeting G-quadruplex DNA as cognitive function therapy for ATR-X syndrome.","volume":"24","author":"Shioda","year":"2018","journal-title":"Nat Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1093\/nar\/gkaa281","article-title":"High specificity and tight spatial restriction of self-biotinylation by DNA and RNA G-Quadruplexes complexed in vitro and in vivo with heme.","volume":"48","author":"Lat","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cga.12365","article-title":"5-aminolevulinic acid can ameliorate language dysfunction of patients with ATR-X syndrome.","volume":"60","author":"Wada","year":"2020","journal-title":"Congenit Anom (Kyoto)"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s13300-022-01335-8","article-title":"Pilot trial on the effect of 5-aminolevulinic acid on glucose tolerance in patients with maternally inherited diabetes and deafness.","volume":"14","author":"Nakamura","year":"2022","journal-title":"Diabetes Ther"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virol.2018.11.016","article-title":"Heme oxygenase-1 agonist CoPP suppresses influenza virus replication through IRF3-mediated generation of IFN-\u03b1\/\u03b2.","volume":"528","author":"Ma","year":"2019","journal-title":"Virology"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/jam.13038","article-title":"Inactivation of dengue and yellow fever viruses by heme, cobalt-protoporphyrin IX and tin-protoporphyrin IX.","volume":"120","author":"Assun\u00e7\u00e3o-Miranda","year":"2016","journal-title":"J Appl Microbiol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"e00053","DOI":"10.1128\/AAC.00053-17","article-title":"Mechanisms of vesicular stomatitis virus inactivation by protoporphyrin IX, zinc-protoporphyrin IX, and mesoporphyrin IX.","volume":"61","author":"Cruz-Oliveira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"9805","DOI":"10.1038\/s41598-018-27855-7","article-title":"Co-protoporphyrin IX and Sn-protoporphyrin IX inactivate Zika, Chikungunya and other arboviruses by targeting the viral envelope.","volume":"8","author":"Neris","year":"2018","journal-title":"Sci Rep"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1139\/o04-006","article-title":"Protective role of heme oxygenase in the blood vessel wall during atherogenesis.","volume":"82","author":"Hoekstra","year":"2004","journal-title":"Biochem Cell Biol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"647189","DOI":"10.3389\/fvets.2021.647189","article-title":"Possible antiviral activity of 5-aminolevulinic acid in feline infectious peritonitis virus (feline coronavirus) infection.","volume":"8","author":"Takano","year":"2021","journal-title":"Front Vet Sci"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/pathogens11020164","article-title":"Antiviral effects of 5-aminolevulinic acid phosphate against classical swine fever virus: in vitro and in vivo evaluation.","volume":"11","author":"Hirose","year":"2022","journal-title":"Pathogens"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e0281399","DOI":"10.1371\/journal.pone.0281399","article-title":"Suppression of angiotensin converting enzyme 2, a host receptor for SARS-CoV-2 infection, using 5-aminolevulinic acid in vitro.","volume":"18","author":"Nara","year":"2023","journal-title":"PLoS One"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1128\/AAC.01910-15","article-title":"In vivo curative and protective potential of orally administered 5-aminolevulinic acid plus ferrous ion against malaria.","volume":"59","author":"Suzuki","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.scib.2020.12.005","article-title":"Protoporphyrin IX and verteporfin potentially inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2.","volume":"66","author":"Gu","year":"2021","journal-title":"Sci Bull"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbrc.2021.01.091","article-title":"5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro.","volume":"545","author":"Sakurai","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41182-021-00397-x","article-title":"Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2.","volume":"50","author":"Ngwe Tun","year":"2022","journal-title":"Trop Med Health"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.healun.2014.09.037","article-title":"5-Aminolevulinic acid with ferrous iron induces permanent cardiac allograft acceptance in mice via induction of regulatory cells.","volume":"34","author":"Hou","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"e0252964","DOI":"10.1371\/journal.pone.0252964","article-title":"Detection of SARS-CoV-2 using qRT-PCR in saliva obtained from asymptomatic or mild COVID-19 patients, comparative analysis with matched nasopharyngeal samples.","volume":"16","author":"Ota","year":"2021","journal-title":"PLoS One"},{"key":"R38-20250504","first-page":"15","article-title":"Phase 2 randomized clinical trial of 5-aminolevulinic acid plus sodium citrate chloride vs placebo for Covid-19 infected patients recovered with sequelae.","volume":"10","author":"Imamura","year":"2022","journal-title":"ALA-Porphyrin Sci"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/infdis\/jiac136","article-title":"Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review.","volume":"226","author":"Chen","year":"2022","journal-title":"J Infect Dis"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"n1648","DOI":"10.1136\/bmj.n1648","article-title":"Long covid-mechanisms, risk factors, and management.","volume":"374","author":"Crook","year":"2021","journal-title":"BMJ"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.bbrc.2016.01.136","article-title":"5-Aminolevulinic acid combined with ferrous iron ameliorate ischemia-reperfusion injury in the mouse fatty liver model.","volume":"470","author":"Li","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12865-018-0277-5","article-title":"5-Aminolevulinic acid regulates the immune response in LPS-stimulated RAW 264.7 macrophages.","volume":"19","author":"Sugiyama","year":"2018","journal-title":"BMC Immunol"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"100228","DOI":"10.1016\/j.bonr.2019.100228","article-title":"Nrf2 activation in osteoblasts suppresses osteoclastogenesis via inhibiting IL-6 expression.","volume":"11","author":"Narimiya","year":"2019","journal-title":"Bone Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:03:09Z","timestamp":1746327789000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":38,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034858","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}